PMID: 11342895May 9, 2001Paper

Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial

The Journal of Urology
J Malone-LeeC Powell

Abstract

We compared the tolerability and clinical efficacy of tolterodine with those of oxybutynin in patients with an overactive bladder using an upward oxybutynin dose titration strategy analogous to that used in routine clinical practice in the United Kingdom and Republic of Ireland. In a randomized double-blind trial 378 male and female patients 50 years old or older with symptoms of overactive bladder (a urinary frequency of 8 or more voids per 24 hours with urgency and/or urge incontinence, that is 1 or more urge incontinence episodes per 24 hours) received 10 weeks of treatment with 2 mg. tolterodine twice daily/or an initial dose of 2.5 mg. oxybutynin twice daily, increasing to 5 mg. twice daily after 2 weeks of treatment. The main outcome measures were changes in voiding diary variables combined with detailed tolerability-safety assessments. Patients treated with tolterodine had significantly fewer adverse events (69% versus 81%, p = 0.01), notably dry mouth (37% versus 61%, p <0.0001), as well as a lower incidence of dose reduction (6% versus 25%, p <0.0001) than those in the oxybutynin group. Each agent had comparable efficacy for improving urinary symptoms. Tolterodine and oxybutynin caused a significant decrease (p = 0.000...Continue Reading

References

Dec 1, 1979·British Journal of Urology·R C FeneleyJ Blannin
Apr 18, 1992·BMJ : British Medical Journal·J Malone-LeeG Szonyi
Mar 1, 1980·British Journal of Obstetrics and Gynaecology·L D Cardozo, S L Stanton
May 30, 1997·European Journal of Pharmacology·L NilvebrantB Sparf
Jan 9, 1998·British Journal of Obstetrics and Gynaecology·C J KelleherS Salvatore
Mar 12, 1998·Urology·R A Appell
Oct 17, 1998·Neurourology and Urodynamics·P E Van KerrebroeckJ M Soler
Dec 9, 1995·PharmacoEconomics·W R LenderkingM A Testa
Oct 30, 1999·International Urogynecology Journal and Pelvic Floor Dysfunction·H P DrutzS Radomski

❮ Previous
Next ❯

Citations

Feb 14, 2013·Der Urologe. Ausg. A·B AmendK-D Sievert
Jan 11, 2007·International Urogynecology Journal and Pelvic Floor Dysfunction·J MetelloH Retto
Jul 27, 2006·International Urology and Nephrology·Dionisios MitropoulosAris Giannopoulos
Oct 2, 2002·Current Urology Reports·H Henry LaiRodney A Appell
Feb 14, 2002·Australian Family Physician
Feb 20, 2004·The New England Journal of Medicine·Joseph G Ouslander
Jul 25, 2009·International Journal of Clinical Practice·T L GrieblingM Carlsson
Sep 3, 2010·Drugs & Aging·Stephen R KrausTomas L Griebling
Nov 5, 2013·International Journal of Pharmaceutics·Roshan PradhanJong Oh Kim
Dec 21, 2004·Der Internist·M OelkeU Jonas
Oct 1, 2013·Taiwanese Journal of Obstetrics & Gynecology·Chiu-Lin WangCheng-Yu Long
Aug 16, 2003·British Journal of Clinical Pharmacology·C BroadhurstJ K Dhesi
Oct 10, 2007·BJU International·Paul Abrams, Karl-Erik Andersson
Jan 12, 2005·The Journal of Urology·Richard Darling, Donald Neilson
Oct 26, 2006·Clinical Therapeutics·Maria ManiscalcoRolando Torres-Colón
Oct 27, 2004·Expert Opinion on Pharmacotherapy·Yoram Abramov, Peter K Sand
Aug 3, 2001·American Journal of Obstetrics and Gynecology·M A HarveyG A Wells
Sep 21, 2016·Current Medical Research and Opinion·Michael L GanzXuemei Luo
Jul 13, 2006·International Journal of Urology : Official Journal of the Japanese Urological Association·Paul AbramsUNKNOWN 1032 Study Group
Apr 22, 2008·Expert Opinion on Pharmacotherapy·Stefano SalvatorePierfrancesco Bolis
Jun 27, 2002·Expert Opinion on Pharmacotherapy·Alan D Garely, Lara J Burrows
May 14, 2016·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Jose Carlos TruzziRicardo Reges
Dec 25, 2003·Neurourology and Urodynamics·R J Millard, UNKNOWN Asia Pacific Tolterodine Study Group
Jul 11, 2012·Urologia Internationalis·A D AsimakopoulosE Finazzi-Agrò
Feb 18, 2011·Urologia Internationalis·Yasuhide KitagawaMikio Namiki
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Priya MadhuvrataE Jean C Hay-Smith

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.